A comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma.
A comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma.
复制标题
DOI：
10.18632/oncotarget.24075
复制
发表时间：
2018-01-23
期刊：
影响因子：
--
通讯作者：
Inagaki H
中科院分区：
文献类型：
--
作者：
Sakane T;Murase T;Okuda K;Takino H;Masaki A;Oda R;Watanabe T;Kawano O;Haneda H;Moriyama S;Saito Y;Yamada T;Nakanishi R;Inagaki H
目前，美国食品药品监督管理局注册了四种免疫组织化学检测方法，用于检测PD-L1的表达。我们使用这四种诊断检测方法研究了胸腺癌中PD-L1的表达。对53例患者的病例进行了审查，并使用不同抗体（SP 142、SP 263、22 C3和28-8）对他们的标本进行了4次PD-L1检测。评价肿瘤细胞（TC）和免疫细胞（IC）中的PD-L1表达。在TC中，四种测定在每种情况下均显示出相似的评分。组织学上，鳞状细胞癌（SqCC）中观察到高TC评分。同时，在四种测定中IC评分之间没有显著的相关性。在SqCC中，TC中PD-L1的高表达（定义为≥ 50%TC评分）倾向于与早期癌症相关。PD-L1表达水平高的患者在22 C3测定中倾向于显示出更长的总生存期（p=0.0200）。在胸腺癌中，当TC（而不是IC）染色时，四种检测方法的染色模式显示出高度一致性。TC中PD-L1的高阳性，特别是在SqCC中，表明PD-1/PD-L1靶向治疗可能是一种有前途的治疗方法。
Currently, four immunohistochemical assays are registered with the US Food and Drug Administration to detect the expression of PD-L1. We investigated the PD-L1 expression in thymic carcinomas using these four diagnostic assays. The cases of 53 patients were reviewed and their specimens were subjected to four PD-L1 assays with different antibodies (SP142, SP263, 22C3, and 28-8). The PD-L1 expression in tumor cells (TCs) and immune cells (ICs) was evaluated. In TCs, the four assays showed similar scores in each case. Histopathologically, high TC scores were observed in squamous cell carcinomas (SqCCs). Meanwhile, there were no significant relationships among the IC scores in the four assays. In SqCCs, the high expression of PD-L1 (defined as ≥50% TC score) in TCs tended to be associated with early stage cancer. The patients with high expression levels of PD-L1 tended to show longer overall survival in the 22C3 assays (p=0.0200). In thymic carcinomas, the staining pattern showed high concordance among the four assays when TCs – rather than ICs – were stained. High PD-L1 positivity in TCs, especially in SqCCs, indicated that PD-1/PD-L1 targeted therapy may be a promising therapeutic approach.